GlassScriptPhysician profile
Vincent Dipietro
NPI 1619948791
$1,355.98
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,077 · 2020: $255 · 2022: $23.83.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $244.67 | 2019-2020 | |
| Amgen INC. | $235.12 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $182.78 | 2019-2020 | |
| Lilly USA, LLC | $103.00 | 2019-2020 | |
| Amarin Pharma, INC. | $81.93 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $77.94 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $66.69 | 2019-2020 | |
| Glaxosmithkline, LLC. | $62.40 | 2019-2020 | |
| Sanofi Pasteur INC. | $49.03 | 2019-2020 | |
| Abbvie INC. | $47.87 | 2019 | |
| Boston Scientific Corporation | $33.74 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $26.46 | 2019 | |
| Pfizer INC. | $24.84 | 2019 | |
| Dexcom, INC. | $23.83 | 2022 | |
| Phadia US INC. | $21.75 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $18.23 | 2019 | |
| Genentech USA, INC. | $17.42 | 2019 | |
| Astellas Pharma US INC | $15.93 | 2019 | |
| Sunovion Pharmaceuticals INC. | $11.39 | 2019 | |
| Allergan, INC. | $10.96 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Dipietro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.